Integrated sTim-3 and PLA2R-Ab Levels Improve Risk Stratification in PLA2R-Positive Membranous Nephropathy
Nephron · 2026
DOI: 10.1159/000550248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephron, 2026. Verfasst von Tianyu Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Autoantibodies. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
The utility of M-type phospholipase A2 receptor antibody (PLA2R-Ab) for risk stratification in membranous nephropathy (MN) remains suboptimal, while soluble T-cell immunoglobulin and mucin-domain containing-3 (sTim-3) has been confirmed as a critical immune regulator in kidney diseases. This study investigated the prognostic value of sTim-3 in PLA2R-associated MN (PMN) and the efficacy of its combination with PLA2R-Ab.
Methods
Serum PLA2R-Ab and sTim-3 levels were measured at baseline in 50 PMN patients using highly sensitive time-resolved fluorescence immunoassay (TRFIA) method. Patients were stratified into complete remission, partial remission, and no remission (NR) groups according to 12-month treatment outcomes.
Results
Prognostic cut-off discriminating NR from remission: sTim-3 = 17.63 ng/mL; PLA2R-Ab = 50 RU/mL (KDIGO high-risk threshold). The non-remission rate for patients with PLA2R-Ab 50 RU/mL), sTim-3 demonstrated 93.75% accuracy in predicting outcomes. Remarkably, all 8 patients who achieved actual remission exhibited sTim-3 levels below 17.63 ng/mL. Double positivity (PLA2R-Ab >50 RU/mL and sTim-3 >17.63 ng/mL) identified a refractory subgroup with significantly poorer treatment response compared to other groups. Conclusion: sTim-3 serves as a complementary biomarker to PLA2R-Ab. Combined detection optimizes PMN risk stratification: PLA2R-Ab >50 RU/mL and sTim-3 >17.63 ng/mL indicates an immune-activated state requiring intensive immunosuppression, preventing overtreatment in PLA2R-Ab-high patients with favorable immune status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
- Department of Nephrology (Key Laboratory of Kidney Disease Prevention and Control Technology), Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Nephrology, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Provincial Key Laboratory for Research and Translation on the Syndrome of Kidney Deficiency Accompanied by Blood Stasis and Turbidity, Hangzhou, China.
- Department of Nuclear Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, haiyangao330@sina.com.
- College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China, jswxhb@163.com.
Zitieren
APA
Zheng, T., Du, Y., Tang, X., Shao, X., Chen, L., Kao, S., Qin, Y., Zhou, X., Zhao, X., Gao, H., & Huang, B. (2026). Integrated sTim-3 and PLA2R-Ab Levels Improve Risk Stratification in PLA2R-Positive Membranous Nephropathy. Nephron. https://doi.org/10.1159/000550248
Vancouver
Zheng T, Du Y, Tang X, Shao X, Chen L, Kao S, et al. Integrated sTim-3 and PLA2R-Ab Levels Improve Risk Stratification in PLA2R-Positive Membranous Nephropathy. Nephron. 2026. doi:10.1159/000550248
BibTeX
@article{Zheng2026,
author = {Zheng, Tianyu and Du, Yuanyuan and Tang, Xuanli and Shao, Xiang and Chen, Lingli and Kao, Shangbin and Qin, Yuan and Zhou, Xiumei and Zhao, Xueqin and Gao, Haiyan and Huang, Biao},
title = {Integrated sTim-3 and PLA2R-Ab Levels Improve Risk Stratification in PLA2R-Positive Membranous Nephropathy},
journal = {Nephron},
year = {2026},
doi = {10.1159/000550248}
}
EUVIMED